Cronos Group Reports 2023 Second Quarter Results Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense savings target to $20 to $25 million...
Cronos Group Reports 2023 First Quarter Results Industry-leading balance sheet with $836 million in cash and short-term investments Targeting positive cash flow in 2024 Net revenue in Canada increased...
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated...
Cronos Group Reports 2022 Third Quarter Results Reported consolidated net revenue increased 3% year-over-year to $20.9 million; on a constant currency basis, consolidated net revenue increased 7% year-over-year to...
SEC Charges Canadian Cannabis Company and Former Senior Executive with Accounting Fraud Washington D.C., Oct. 24, 2022 — The Securities and Exchange Commission today charged Cronos Group Inc., a...
Cronos Group Reports 2022 Second Quarter Results Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net revenue increased by 212% year-over-year to $7.2...
Consolidated net revenue increased by 99% year-over-year to $25.0 million in Q1 2022 Israel net revenue increased by 263% year-over-year to $9.1 million in Q1 2022 Increased market share...
Cronos Group Reports 2021 Fourth Quarter and Full-Year Results Consolidated net revenue increased 59% in Full Year 2021 compared to Full Year 2020 Announces the planned exit of its...
Cronos Group Reports 2021 Third Quarter Results Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies Consolidated net...
Cronos Group Files Form 12b-25 TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) today announced that it has...
You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to...
Exclusive Interview with PharmaCann CEO Brett Novey Private multi-state operator PharmaCann relies on a formula supported by its people, its foundational assets and financial discipline. CEO Brett Novey last...
Cronos Group Reports 2021 Second Quarter Results Amended agreement with Ginkgo Bioworks to accelerate commercialization of cultured cannabinoids Announced strategic investment in PharmaCann, a leading U.S. cannabis company Spinach™...
Cronos Group Announces Strategic Investment in PharmaCann, a Leading U.S. Cannabis Company Investment is Expected to Position Cronos Group to Benefit from Rapid Growth in the U.S. Cannabis Market PharmaCann...
Cronos Group Reports 2021 First Quarter Results Receives processing license for the commercial production and sale of cannabinoids using biosynthesis Announces plans to launch Spinach™ branded edibles to the...
Cronos Group Reports 2020 Fourth Quarter and Full-Year Results Announces plans to launch Happy Dance™ in ULTA Beauty™ Cronos Israel continues to grow the PEACE NATURALS™ brand in the...
Cronos Group Reports 2020 Third Quarter Results Kurt Schmidt appointed President and CEO; Mike Gorenstein appointed Executive Chairman Launched a new hemp-derived CBD brand, Happy Dance™, in the U.S....
Cronos Group Announces Expanded Leadership Structure to Drive Next Phase of Growth 30-Year CPG Executive Kurt Schmidt Joins Cronos as Chief Executive Officer and Mike Gorenstein Named Executive Chairman...
Cronos Group Reports 2020 First Quarter Results Fermented target cannabinoid, CBGA, using cannabinoid strains at Cronos Fermentation R&D labs Successfully completed first dried flower shipment to Israel, as Cronos...
Cronos Group Reports 2019 Fourth Quarter and Full-Year Results Completed Audit Committee Review and Restated Certain 2019 Unaudited Interim Financial Statements Expanded Canadian distribution to new provinces and product...
Cronos Group to Restate Certain 2019 Unaudited Interim Financial Statements TORONTO, March 17, 2020 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”)...
Cronos Group Inc. Announces Third Quarter 2019 Results Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced...
MediPharm Labs and Cronos Group Enter Private Label Contract Manufacturing Agreement MediPharm to produce high-quality cannabis concentrate filled vapes for Cronos Group Deal reinforces MediPharm Labs’ leadership in large...
Cronos Group Inc. Announces Second Quarter and First-Half 2019 Results Opened Cronos Device Labs, New Global R&D Center in Israel Appointed Dr. Todd Abraham as Chief Innovation Officer Announced Agreement to Acquire...
Cronos Group Establishes New Growth Opportunity in the United States with Acquisition of Hemp-Based Products Platform TORONTO, Aug. 02, 2019 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX:...
